MarkWide Research

Sale!

Acquired Hemophilia Treatment Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: August, 2022
No of Pages: 168
Delivery Format: PDF + Excel

$2,950.00

Report Description

The Acquired Hemophilia Treatment Market is expected to expand by a compound annual rate of 3.3 percent from 2021-2029. The growth is driven by the increasing rate of prophylactic treatment of patients. The report covers both qualitative and quantitative aspects of the Acquired Hemophilia Market. It examines the main drivers, the issues it is facing, the market expansion opportunities, and its prospects for the future.

Acquired Hemophilia Treatment Market: Overview

Acquired Hemophilia (AH) can be described as a rare auto-immune condition that seriously hinders the body’s ability to create a clot in the event of bleeding. This occurs in those with no relatives with a history of illnesses related to coagulation or clotting. In the body, inhibitors (antibodies) attack the clotting factors, particularly factor VIII, which is the most common cause of Acquired Hemophilia. Clotting factors are proteins needed to ensure that blood clots are formed typically. In the end, people affected develop problems resulting from massive bleeding into muscles and soft tissues, such as skin. At times, AH is also linked to medical issues like cancer, tumors, and pregnancy, other than ulcerative colitis, rheumatoid arthritis, and psoriasis.

The market has been classified and sub-categorized according to the type, treatment, therapeutic Areas, End-Users, and Regional basis. When looking at this market in terms of Type, Hemophilia A presides the market by 50-60 percent and is the more severe type. In contrast, Hemophilia B accounts for only 20 percent of market value.

An Increasing Presence of AH in Newborn requires effective treatment.

The most compelling reasons for this market are the rising incidence of Acquired Hemophilia among newborns and rising diagnosis rates, increasing the need for prophylactic treatments, growing awareness among individuals, growing number of auto-immune disorders, and favorable reimbursement policies. In general, AH is found in older people and has the highest mortality rate, 21%, if not treated. Hemophilia A is the most serious and frequently encountered form of acquired Hemophilia. The difficulties faced by the AH Treatment Market are the high cost of treatment, which hinders access to therapy in middle and low-income countries, a lack of access and availability of new medications, and the adoption rate of the most technologically advanced drugs meager.

Healthcare Infrastructure in NA Offers Effective Access to Therapeutic Options

Based on regional segmentation, the Acquired Hemophilia Treatment Market includes North America, Latin America, Europe, Asia Pacific, Middle East, Africa, and the Rest of the World. North America will dominate the AH Treatment Market by 2020. The main drivers for the market in North America have been U.S. patients diagnosed at a younger age, increasing awareness among patients, better healthcare facilities, and the favorable reimbursement for medications prescribed for an acquired hemophilia treatment increases the development of the market in the region. In the end, European Medical Agency (EMA) has created a supportive regulatory environment by approving the FastTrack classification of drug discovery and the development of medicines to treat acquired hemophilia, putting Europe in the second position. The major players in this market are Baxter Healthcare Corporation, Biogen, The Mueller Health Foundation, Shire (Baxalta), CSL Behring, Pfizer, Inc., Bayer AG, Bioxcel Therapeutics, Ferring Pharmaceuticals, Spark Therapeutics Inc., F. HOFFMAN LA ROCHE, Sanofi, Genentech, Inc., Novo Nordisk, GlaxoSmithKline Plc as well as Bristol-Myers Squibb. Industry leaders are focused on developing Research and Development activities, new products, and launches.

Historical & Forecast Period

This report analyzes each segment from 2019 until 2029, taking 2020 as the year of base for the study. Compounded annual growth rates (CAGR) of each piece are calculated for the forecast period from 2021 until 2029.

Acquired Hemophilia Treatment Market  Report Scope and Segmentation 
 
ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

Report Scope by Segments

CAGR and market revenues were calculated using the primary and secondary studies. Both qualitative and quantitative patterns were considered for the extrapolation of market revenue. Market estimates derived from the research were then validated using top-down, bottom-up strategies and primary research. The market is limited to the following categories of products and regions.

Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa
    • Rest of MEA

Table of Contents

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2.Research Scope
1.3.Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2.Bottom-Up Approach
1.3.5.Assumptions
1.3.7. Market Segmentation

Chapter 2. Executive Summary
2.1. Acquired Hemophilia Treatment Market Portraiture
2.2. Acquired Hemophilia Treatment Market, by type, 2020 (US$ Mn)
2.3. Acquired Hemophilia Treatment Market, by treatment, 2020 (US$ Mn)
2.4. Acquired Hemophilia Treatment Market, by type of therapeutic area, 2020 (US$ Mn)
2.5. Acquired Hemophilia Treatment Market, by type of end user, 2020 (US$ Mn)
2.6. Acquired Hemophilia Treatment Market, by Geography, 2020 (Value)
2.7. Impact of Covid – 19

Chapter 3. Acquired Hemophilia Treatment Market: Market Dynamics and Future Outlook
3.1.Market Overview
3.2. Current Scenario: New Product Launches, Increase in Animal Free Testing
3.3. Drivers
3.3.1. Increasing prevalence of Hemophilia in neonatal population
3.3.2. Rising testing rates
3.3.3 Prophylactic treatment used more often
3.4. Challenges
3.4.1. High Cost of Treatment
3.4.2. Lack of Knowledge
3.5. Opportunities
3.7. Attractive Investment Proposition, by Geography, 2020
3.7. Competitive Landscape (Key Players)
3.7.1. Mergers and Acquisition Analysis
3.7.2. Agreements, Collaborations and Partnership
3.7.3. New Product Launches

Chapter 4. Acquired Hemophilia Treatment Market, By Type, 2019 2029 (US$ Mn)
4.1. Overview
4.2. Hemophilia A
4.3. Hemophilia B
4.4. Hemophilia C
4.5. Others

Chapter 5. Acquired Hemophilia Treatment Market, By Treatment, 2019 2029 (US$ Mn)
5.1. Overview
5.2. On-Demand
5.3. Prophylaxis

Chapter 6. Acquired Hemophilia Treatment Market, By Therapeutic Areas, 2019 2029 (US$ Mn)
6.1. Overview
6.2. Replacement Therapy
6.3. Gene Therapy
6.4. Immune Tolerance Induction Therapy
6.5. Others

Chapter 7. Acquired Hemophilia Treatment Market, By Type of End User, 2019 2029 (US$ Mn)
7.1. Overview
7.2. Hospitals
7.3. Clinics
7.4. Others

Chapter 8. Acquired Hemophilia Treatment, By Regional Market Analysis, 2019 2029 (US$ Mn)
8.1. Definition & Scope
8.2. Regional Market Share Analysis, 2019& 2029
8.3. Regional Market Dashboard
8.4. Regional Market Snapshot
8.5. Regional Market Share Analysis 2019 to 2029
8.5.1. North America
8.5.2. Europe
8.5.3. Asia Pacific
8.5.4. Latin America
8.5.5. Middle East and Africa
8.6. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
8.6.1. North America
8.6.2. Europe
8.6.3. Asia Pacific
8.6.4. Latin America
8.6.5. Middle East and Africa
8.7. Market Size, & Forecasts, Revenue and Trend Analysis, 2019 to 2029

Chapter 9. North America Acquired Hemophilia Treatment, Regional Market Analysis, 2019 2029 (US$ Mn)
9.1. North America Acquired Hemophilia Treatment Market Analysis, 2019-2029
9.2. North America Acquired Hemophilia Treatment Market, by type, 2019 2029 (US$ Mn)
9.3. North America Acquired Hemophilia Treatment Market, by treatment, 2019 2029 (US$ Mn)
9.4. North America Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 2029 (US$ Mn)
9.5. North America Acquired Hemophilia Treatment Market, by end user, 2019 2029 (US$ Mn)
9.6. North America Acquired Hemophilia Treatment Market, by region, 2019 2029 (US$ Mn)
9.6.1. U.S.
9.6.2. Canada

Chapter 10. Latin America Acquired Hemophilia Treatment, Regional Market Analysis, 2019 2029 (US$ Mn)
10.1. Latin America Acquired Hemophilia Treatment Market Analysis, 2019-2029
10.2. Latin America Acquired Hemophilia Treatment Market, by type, 2019 2029 (US$ Mn)
10.3. Latin America Acquired Hemophilia Treatment Market, by treatment, 2019 2029 (US$ Mn)
10.4. Latin America Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 2029 (US$ Mn)
10.5. Latin America Acquired Hemophilia Treatment Market, by end user, 2019 2029 (US$ Mn)
10.6. Latin America Acquired Hemophilia Treatment Market, by region, 2019 2029 (US$ Mn)
10.6.1. Brazil
10.6.2. Argentina
10.6.3. Mexico

Chapter 11. Europe Acquired Hemophilia Treatment, Regional Market Analysis, 2019 2029 (US$ Mn)
11.1. Europe Acquired Hemophilia Treatment Market Analysis, 2019-2029
11.2. Europe Acquired Hemophilia Treatment Market, by type, 2019 2029 (US$ Mn)
11.3. Europe Acquired Hemophilia Treatment Market, by treatment, 2019 2029 (US$ Mn)
11.4. Europe Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 2029 (US$ Mn)
11.5. Europe Acquired Hemophilia Treatment Market, by end-user, 2019 2029 (US$ Mn)
11.6. Europe Acquired Hemophilia Treatment Market, by region, 2019 2029 (US$ Mn)
11.6.1. United Kingdom
11.6.2. Germany
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe

Chapter 12. Asia Pacific Acquired Hemophilia Treatment, Regional Market Analysis, 2019 2029 (US$ Mn)
12.1. Asia Pacific Acquired Hemophilia Treatment Market Analysis, 2019-2029
12.2. Asia Pacific Acquired Hemophilia Treatment Market, by type, 2019 2029 (US$ Mn)
12.3. Asia Pacific Acquired Hemophilia Treatment Market, by treatment, 2019 2029 (US$ Mn)
12.4. Asia Pacific Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 2029 (US$ Mn)
12.5. Asia Pacific Acquired Hemophilia Treatment Market, by end-user, 2019 2029 (US$ Mn)
12.6. Asia Pacific Acquired Hemophilia Treatment Market, by region, 2019 2029 (US$ Mn)
12.6.1. Japan
12.6.2. China
12.6.3. India
12.6.4. ASEAN
12.6.5. Rest of APAC

Chapter 13. Middle East & Africa (MEA)Acquired Hemophilia Treatment, Regional Market Analysis, 2019 2029 (US$ Mn)
13.1. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market Analysis, 2019 2029
13.2. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by type, 2019 2029 (US$ Mn)
13.3. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by treatment, 2019 2029 (US$ Mn)
13.4. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by therapeutic areas, 2019 2029 (US$ Mn)
13.5. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by end-user, 2019 2029 (US$ Mn)
13.6. Middle East & Africa (MEA) Acquired Hemophilia Treatment Market, by region, 2019 2029 (US$ Mn)
13.6.1. Saudi Arabia
13.6.2. United Arab Emirates
13.6.3. South Africa
13.6.4. Rest of MEA

Chapter 14. Company Profiles
14.1. Baxter Healthcare Corporation
14.2. Biogen
14.3. Pfizer
14.4. F. HOFFMAN LA ROCHE
14.5. Sanofi
14.6. Inveni AI
14.7. Genentech, Inc.
14.8. Bristol-Myers Squibb
14.9.BioXcel Therapeutics Inc.
14.10. GlaxoSmithKline, Plc
14.11.Shire (Baxalta)
14.12.CSL Behring
14.13.Bayer AG
14.14.Spark Therapeutics Inc.
14.15.The Mueller Health Foundation

Segmentation

CAGR and market revenues were calculated using the primary and secondary studies. Both qualitative and quantitative patterns were considered for the extrapolation of market revenue. Market estimates derived from the research were then validated using top-down, bottom-up strategies and primary research. The market is limited to the following categories of products and regions.

 

Major Companies

Corporation, Biogen, The Mueller Health Foundation, Shire (Baxalta), CSL Behring, Pfizer, Inc., Bayer AG, Bioxcel Therapeutics, Ferring Pharmaceuticals, Spark Therapeutics Inc., F. HOFFMAN LA ROCHE, Sanofi, Genentech, Inc., Novo Nordisk, GlaxoSmithKline Plc as well as Bristol-Myers Squibb. Industry leaders are focused on developing Research and Development activities, new products, and launches.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF